The emerging treatment landscape in ATTR amyloidosis: what’s on the horizon?

28 August 2018 (13:29 - 13:45)

Organised by:

About the speaker

Professor Claudio Rapezzi

University of Ferrara, Ferrara (Italy)

4 More presentations in this session

Presentation thumbnail

Welcome and introduction - Amyloidosis beyond heart failure: paving the way for an early diagnosis.

Doctor M. Grogan (Rochester, US)

Presentation thumbnail

Delayed diagnosis of amyloidosis: what if the patient does not have heart failure?

Doctor M. Grogan (Rochester, US)

Presentation thumbnail

Managing amyloidosis in cardiology practice: a call for collaboration.

Doctor M. Maurer (New York, US)

Presentation thumbnail

Panel discussion and question and answer session - Amyloidosis beyond heart failure: paving the way for an early diagnosis.

Doctor M. Grogan (Rochester, US)

Access the full session

Session thumbnail

Amyloidosis beyond heart failure: paving the way for an early diagnosis

The Event

ESC Congress 2018

28 August 2018 13:29 CET

You may be interested in

Congress Session

Cardiac amyloidosis: when translational approaches and personalised medicine become reality

13 May 2024

Congress Presentation

Patients with transthyretin amyloid cardiomyopathy may have preserved, mildly reduced, or reduced ejection fraction

27 August 2021

Congress Presentation

Cardiovascular events in patients diagnosed with light chain amyloidosis in the USA: a real-world analysis utilizing electronic health records

20 June 2025

Congress Presentation

Transthyretin-directed antisense oligonucleotide therapy effects on ATTRv myocardiopathy

20 May 2023

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources